Bristol-Myers Squibb Company (BMY)
Here is What to Know Beyond Why Bristol Myers Squibb Company (BMY) is a Trending Stock
Bristol Myers (BMY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Bristol Myers (BMY) Upgraded to Buy: Here's What You Should Know
Bristol Myers (BMY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
BMY or VRTX: Which Is the Better Value Stock Right Now?
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Bristol Myers Squibb (BMY) and Vertex Pharmaceuticals (VRTX). But which of these two stocks offers value investors a better bang for their buck right now?
A Market Crash Could Ruin Baby Boomers: 5 Safe High-Yield Dividend Stocks and Advice
24/7 Wall St. Insights The 2025 Social Security COLA will be only 2.5%.
Bristol Myers Squibb (BMY) Stock Falls Amid Market Uptick: What Investors Need to Know
In the closing of the recent trading day, Bristol Myers Squibb (BMY) stood at $52.20, denoting a -0.38% change from the preceding trading day.
BMY Buoyed by Recent Regulatory Updates: How to Play the Stock?
While the recent spate of positive regulatory updates boosts Bristol Myers, we will advise a wait-and-watch strategy.
Is Trending Stock Bristol Myers Squibb Company (BMY) a Buy Now?
Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Bristol Myers Squibb: A High-Yield Bargain With Growth On The Horizon
Frequent trading can erode gains due to transaction costs and taxes; a buy-and-hold strategy is often more effective for retail investors. Bristol Myers Squibb offers a strong dividend yield, below-average valuation, and solid growth prospects, making it a compelling buy. BMY's robust pipeline, including advancements in neurodegenerative therapies, and strong balance sheet support future growth and income potential.
Bristol Myers Squibb (BMY) Advances While Market Declines: Some Information for Investors
The latest trading day saw Bristol Myers Squibb (BMY) settling at $54.20, representing a +0.82% change from its previous close.
2 Passive-Income Stocks to Load Up On in October
These two dividend powerhouses are ideal choices for passive-income investors.
Bristol Myers beats $6.4 billion lawsuit over delayed cancer drug
Bristol Myers Squibb won the dismissal on Monday of a $6.4 billion lawsuit claiming it cheated former Celgene shareholders by delaying federal approval for the cancer drug Breyanzi and two other drugs developed by Celgene.
3 Surprisingly Underrated Stocks to Buy Right Now
Bristol Myers Squibb is trading at a significant discount. Moderna has a lot of irons in the fire.
